Zymeworks (NASDAQ:ZYME) Upgraded at Citizens Jmp

Citizens Jmp upgraded shares of Zymeworks (NASDAQ:ZYME) to a strong-buy rating in a report published on Wednesday morning,Zacks.com reports.

ZYME has been the topic of a number of other research reports. Wells Fargo & Company upgraded shares of Zymeworks to a “hold” rating in a research report on Friday, October 24th. Zacks Research downgraded Zymeworks from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Wall Street Zen lowered Zymeworks from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. B. Riley upgraded Zymeworks to a “strong-buy” rating in a report on Thursday, October 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Zymeworks Stock Performance

NASDAQ:ZYME opened at $26.69 on Wednesday. Zymeworks has a fifty-two week low of $9.03 and a fifty-two week high of $28.49. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -31.77 and a beta of 1.27. The company’s 50 day moving average is $20.21.

Zymeworks (NASDAQ:ZYME) last issued its earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. Zymeworks had a negative net margin of 47.16% and a negative return on equity of 19.25%. The company had revenue of $27.61 million for the quarter, compared to the consensus estimate of $28.27 million.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.